Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Asthma, Allergic Clear all

Conditions: Allergic Diseases, Asthma
Interventions: Vaginal seeding, Placebo Seeding, Standard care, Post-seeding Care; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: New York, New York

Conditions: Allergic Asthma
Interventions: Placebo, Omalizumab, Immunotherapy; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Asthma, Allergy
Interventions: omalizumab; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Allergic Asthma
Interventions: Albuterol sulfate; Drug
Lead sponsor: Respirics Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Allergic Asthma
Interventions: gamma tocopherol, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: Fluticasone propionate HFA 220; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Omalizumab, Placebo, Fluticasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: Asthma, Allergies
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mild Atopic Asthma
Interventions: BITS7201A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Allergic Asthma
Interventions: Natural source d-α-tocopheryl acetate; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Allergic Rhinitis
Interventions: Standardized Ragweed Allergenic Extract, Placebo; Biological
Lead sponsor: Greer Laboratories; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 30
States / cities: Normal, Illinois • Evansville, Indiana • Iowa City, Iowa + 23 more

Conditions: Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal, Asthma
Interventions: Clinical Center Reference Endotoxin (CCRE); Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: Placebo, R940343 1mg, R940343 2mg; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 51
States / cities: Fullerton, California • Los Angeles, California • Mission Viejo, California + 43 more

Conditions: Allergies, Allergic Rhinitis, Asthma
Interventions: sublingual immunotherapy, placebo sublingual immunotherapy; Drug
Lead sponsor: Stanford University; Other
Eligibility: 5 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lung Disease
Interventions: Placebo, Xolair; Drug
Lead sponsor: Creighton University; Other
Eligibility: 12 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Omaha, Nebraska • Albany, New York

Conditions: Meniere Disease, Allergic Rhinitis, Vertigo
Interventions: Montelukast, Placebo; Drug
Lead sponsor: House Ear Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Eosinophilic Esophagitis
Interventions: APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy; Drug · Procedure
Lead sponsor: Ellodi Pharmaceuticals, LP; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more

Conditions: Asthma, Airway Inflammation, Airflow Obstruction, Airway Hyperactivity
Interventions: Pioglitazone Hydrochloride; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland • Falls Church, Virginia

Conditions: Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis
Interventions: Segmental allergen challenge; Biological
Lead sponsor: JOSALYN CHO; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Boston, Massachusetts

Conditions: Asthma, Lung Function Decreased, Food Allergy, Allergic Sensitisation, Allergic Rhinitis, COPD, Atopy
Interventions: Dietary intake of various nutrients, foods and biocompounds; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 15 Years to 75 Years
Enrollment: 3,500 participants
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Up to 99 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: QAW039, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more

Conditions: Allergic Asthma
Interventions: Omalizumab, Placebo, Asthma therapies; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 17 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 100
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more

Conditions: Asthma, Perennial Allergic Rhinitis
Interventions: Mouse Allergenic Extract; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more

Search by objective public record fields.

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab

Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure

Biomarkers of Irritant-Induced and Allergic Asthma

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

Airway Immune Response to Allergens (Use Lay Language Here)

Dietary Intake in Adults From the GA2LEN Folow-up Survey

Allergy and Immunology Natural History Study

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Subcutaneous Immunotherapy for Mouse in Adults